Votrient 400mg

The remedy Votrient 400mg (Pazopanib) belongs to the pharmacological group of antitumor agents, being an inhibitor of protein tyrosine kinase. The active substance in its composition is Pazopanib. Votrient 400mg is used in the treatment of advanced renal cell carcinoma, as well as in the treatment of advanced soft tissue sarcoma in those patients who have already received chemotherapy in the past.

Mechanism of action Votrient 400mg.

Pazopanib is an active inhibitor of a number of tyrosine kinase enzymes. All these enzymes participate in the metabolism of tumor cells, as well as in their growth and reproduction processes. By suppressing the activity of tyrosine kinase, Votrient 400mg shows direct cytotoxic activity, destroying malignantly degenerated cells.

Protocol for the using of Votrient 400mg.

The Votrient 400mg is available in tablet form, and its standard dosage is 800 mg, which are taken once a day. The remedy is taken no later than one hour before meals or not earlier than two hours after it. Tablets should be swallowed whole, not breaking and not chewing them. Correction of the dose depends on the individual response of the patient to this treatment. The correction step is 200 mg, but cannot be less than 400 mg per day. The remedy cannot be combined with taking such remedies as nefazodone, ketoconazole, clarithromycin, and also some other antiviral remedies.

Efficiency of using of Votrient 400mg.

The effectiveness of the application and the safety profile of the Votrient 400mg in the therapy of cancer tumors was investigated for a clinical trial called PALETTE. In his course, the Votrient 400mg demonstrated an increase in the survival of patients without progressing pathology by almost 3-fold compared with patients in the control group. Thanks to such results, the remedy was approved by the FDA and the European Commission.

How to use the drug?

Therapy with Votrient must be supervised by the doctor, experienced in the treatment of cancer. The optimal daily dose is 800 mg; however, it may be decreased if the patient has adverse effects. Votrient must be taken with water (but on an empty stomach), about 1 before or two hours after eating. The pills must be swallowed whole rather than broken or crushed).

Drug studies

The action of Votrient was first researched in experimental models before being studied in patients.

This medication has been compared to placebo in the research involving more than 400 patients suffering from advanced RCC, after a failure of cytokines therapy. The main criterion for efficiency was how long the patients lived without their progression of their disease.

What advantages have been revealed during the research?

Votrient proved to be more efficient than placebo in the treatment of advanced RCC. On the average, the patients who used Votrient lived for nine months without the exacerbation of their disease, compared with four months for the patients using placebo.

Interaction of Votrient 400mg with other remedies.

The starter is not used with substances that affect the metabolism of the CYP3A4 enzyme. These include: ketoconazole and intraconazole, clarithromycin, atazanavir, ritonavir, voriconazole, and several other pharmacological agents.